Exhibit 32.1
CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Oncocyte Corporation (the “Company”) for the quarter ended March 31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Joshua Riggs, President and Chief Executive Officer of the Company, and Andrea James, Chief Financial Officer of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
Date: May 12, 2025
| /s/ Joshua Riggs | 
 | 
| Joshua Riggs | 
 | 
| President and Chief Executive Officer (Principal Executive Officer) | 
 | 
| 
 | 
 | 
| /s/ Andrea James | 
 | 
| Andrea James | 
 | 
| Chief Financial Officer (Principal Financial Officer) | 
 |